A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC
Condition: Unresectable Stage III NSCLC Interventions: Drug: Durvalumab; Drug: Cisplatin/ Etoposide; Drug: Carboplatin/ Paclitaxel; Drug: Pemetrexed/ Cisplatin; Drug: Pemetrexed/ Carboplatin; Radiation: Radiation Sponsor: Shandong Cancer Hospital and Institute Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Cancer & Oncology | China Health | Non-Small Cell Lung Cancer | Research | Study